

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WAI YUEN TONG MEDICINE HOLDINGS LIMITED**

**( 位元堂藥業控股有限公司\* )**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 897)**

**CHANGE OF EXECUTIVE DIRECTORS,  
APPOINTMENT OF COMPANY SECRETARY,  
CHANGE OF AUTHORIZED REPRESENTATIVES  
AND  
CHANGE IN COMPOSITION OF THE EXECUTIVE COMMITTEE**

**CHANGE OF EXECUTIVE DIRECTORS**

The Board announces that with effect from 8 February 2021:

1. Mr. Chan Chun Hong, Thomas has resigned as an executive Director; and
2. Ms. Law Man Yee, Anita has been appointed as an executive Director.

**APPOINTMENT OF COMPANY SECRETARY**

The Board also announces that with effect from 8 February 2021, Mr. Cheung Chin Wa Angus has been appointed as the company secretary of the Company.

**CHANGE OF AUTHORIZED REPRESENTATIVES**

The Board further announces that with effect from 8 February 2021:

1. Mr. Chan Chun Hong, Thomas has ceased to be an authorized representative of the Company for the purposes of Rule 3.05 of the Listing Rules and Part 16 of the Companies Ordinance; and

2. Ms. Tang Wai Man has been appointed as authorized representative of the Company for the purposes of Rule 3.05 of the Listing Rules and Part 16 of the Companies Ordinance.

#### **CHANGE IN COMPOSITION OF THE EXECUTIVE COMMITTEE**

The Board further announces that with effect from 8 February 2021, Mr. Chan Chun Hong, Thomas has ceased to be a member of the Executive Committee of the Company and Ms. Law Man Yee, Anita has been appointed as a member of the Executive Committee of the Company.

#### **CHANGE OF EXECUTIVE DIRECTORS**

The board of directors (the “**Board**” or the “**Director(s)**”) of Wai Yuen Tong Medicine Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) announces that Mr. Chan Chun Hong, Thomas (“**Mr. Chan**”) has resigned as executive Director with effect from 8 February 2021 in order to devote more time to his personal commitments. Mr. Chan confirmed that he has no disagreement with the Board and there is no matter that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company.

The Board expresses its sincere gratitude to Mr. Chan for his valuable contribution to the Group during his tenure of office.

The Board further announces that Ms. Law Man Yee, Anita (“**Ms. Law**”) has been appointed as executive Director with effect from 8 February 2021.

The biographical details of Ms. Law are as follows:

Ms. Law, aged 58, joined the Group in 2004 and is currently the Assistant General Manager – Purchasing Processing of the Group. Ms. Law is responsible for overall strategic planning, sales and marketing, raw material sourcing and retail operation in Hong Kong, Macau and the Mainland China of the Group. She has extensive experience in pharmaceutical industry covering strategic planning, sales and marketing, new products development and production management.

Pursuant to a service agreement entered into between Ms. Law and the Company on 8 February 2021, Ms. Law has been appointed as executive Director for a term of three years commencing from 8 February 2021 and is entitled to an annual remuneration of approximately HK\$480,000 with regard to her duties and responsibilities. She is also entitled to a performance bonus at the discretion of the remuneration committee of the Company and the Board with reference to the Company's performance and the prevailing practice in the industry. Ms. Law will hold office only until the next general meeting of the Company after her appointment and thereafter subject to retirement by rotation and re-election in accordance with the bye-laws of the Company. Save as disclosed above, Ms. Law does not hold any directorship or have any major appointment in any listed public company in the past three years preceding the date of this announcement and does not have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")) of the Company.

As at the date of this announcement, Ms. Law is not deemed to have and does not have any interest in the shares of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, there are no other matters relating to the appointment of Ms. Law that need to be brought to the attention of the shareholders of the Company and there is no other information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

#### **APPOINTMENT OF COMPANY SECRETARY**

The Board also announces that Mr. Cheung Chin Wa Angus ("**Mr. Cheung**") has been appointed as the company secretary of the Company with effect from 8 February 2021.

The biographical details of Mr. Cheung are as follows:

Mr. Cheung is a fellow member of both The Hong Kong Institute of Chartered Secretaries and The Chartered Governance Institute. He holds a Master Degree of Professional Accounting, a Master Degree of Corporate Governance, a Bachelor Degree of Laws and a Bachelor Degree of Arts in Translation. Prior to joining the Group, Mr. Cheung held company secretary positions in several Hong Kong listed companies, including China Agri-Products Exchange Limited (Stock code: 149), an indirect non-wholly owned subsidiary of the Company.

The Board would like to extend its warmest welcome to Ms. Law for joining the Board and Mr. Cheung on his appointment.

## **CHANGE OF AUTHORIZED REPRESENTATIVES**

Following the resignation of Mr. Chan as executive Director with effect from 8 February 2021, Mr. Chan also ceased to be an authorized representative of the Company for the purposes of Rule 3.05 of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Companies Ordinance**”) with effect from 8 February 2021. The Board announces that Ms. Tang Wai Man, an executive Director, has been appointed as authorized representative of the Company for the purposes of Rule 3.05 of the Listing Rules and Part 16 of the Companies Ordinance with effect from 8 February 2021.

## **CHANGE IN COMPOSITION OF THE EXECUTIVE COMMITTEE**

Immediately upon the resignation of Mr. Chan as an executive Director with effect from 8 February 2021, the Board also announces that with effect from 8 February 2021, Mr. Chan has ceased to be a member of the Executive Committee of the Company and Ms. Law Man Yee, Anita has been appointed as a member of the Executive Committee of the Company.

By Order of the Board

**WAI YUEN TONG MEDICINE HOLDINGS LIMITED**

(位元堂藥業控股有限公司\*)

**Tang Ching Ho**

*Chairman and Managing Director*

Hong Kong, 8 February 2021

*As at the date of this announcement, the executive Directors are Mr. Tang Ching Ho, Ms. Tang Mui Fun, Ms. Tang Wai Man and Ms. Law Man Yee, Anita, and the independent non-executive Directors are Mr. Siu Man Ho, Simon, Mr. Leung Wai Ho, Mr. Cho Wing Mou and Mr. Li Ka Fai, David.*

*\* For identification purpose only*